A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

Innovation is never easy. It requires the audacity to create a new path, one where we will encounter novel obstacles that demand both resourcefulness and bold imagination. But when we stand together, ...

Caribou Biosciences Inc. (NASDAQ:CRBU) shares skyrocketed 100% on Monday after the company released promising Phase 1 ...

is a clinical-stage biopharmaceutical company focused on CRISPR genome-editing technology. The company specializes in developing allogeneic CAR-T cell therapies for treating various types of cancer, ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at ...

And I do have several favorite stocks that fit that description. My top growth stock to buy in November is one that I've ...

Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced positive results from its ongoing ...

Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company's genome-editing ...

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell ...

FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging ...